News

A new tool to predict T cell behaviour and improve immunotherapies

17 Nov 2026
A new tool to predict T cell behaviour and improve immunotherapies

T cells are the trained killers of the immune system and the driving force behind cancer immunotherapy.

But the behaviour of T cells is hard to predict: Some spring into action when prompted, while others become lethargic and aimless.

This puzzling inconsistency is one of the main reasons immunotherapies don’t work in most cancer patients.

To tackle this problem, Memorial Sloan Kettering Cancer Centre (MSK) researchers have developed a new approach to better understand and predict T cell behaviour.

The team, led by computational biologists Benjamin Greenbaum, PhD, and Sohrab Shah, PhD, designed a statistical model to monitor T cell responses to immunotherapies, including therapeutic cancer vaccines.

By connecting a T cell’s receptors — which can recognise antigens (protein fragments) on the surface of cancer cells — to how it behaves, the researchers hoped to address a fundamental question: How does a T cell’s genetic identity (the unique genetic sequence of its receptor) relate to its biological behaviour — and how does that behaviour change with immunotherapy?

The researchers used a new computational method, called TCRi (for TCR information), to analyse data from more than 167,000 T cells from cancer patients who had received immunotherapy drugs called checkpoint inhibitors.

“This approach produces a standardised measurement that lets us compare results across different studies and clinical trials,” Dr. Greenbaum says.

“We have a way to learn from this data what a meaningful T cell response to an immunotherapy looks like — or doesn’t.”

The researchers report their findings in Nature Genetics.

The co-first authors were Nicholas Ceglia, PhD, and Sohrab Salehi, PhD, in the laboratory of Dr. Shah, and Zachary Sethna, PhD, in the Olayan Centre for Cancer Vaccines at MSK, directed by Vinod Balachandran, MD.

T cell receptors can recognise and bind to certain antigens present on the surface of cancer cells.

Like a key turning a highly specific lock, the interaction between antigen and receptor will trigger a T cell to make copies of itself with identical receptors that can recognise the same antigens.

This trait is known as receptor clonality.

The presence of many T cells sharing the same receptor suggests a strong anti-cancer immune response.

But the existence of this newly created T cell army can be misleading: Even when the T cells seemingly have the right receptors, they often fail to act when prompted by immunotherapy.

“Looking at clonality alone can lead you to confuse responders with non-responders,” Dr. Greenbaum says.

“The T cells of non-responders can look very clonal, but they don’t behave as if they can still recognise the antigens they should. This new tool can help give us a clearer understanding of T cell behaviour.”

The new model designed by the researchers could shed light on T cell behaviour by examining the relationship between the makeup of these receptors and the actual state of the T cell.

The research draws on information theory, a branch of mathematics created by Claude Shannon in 1948 that studies how information is measured, stored, and sent.

(Anthropic named its artificial intelligence tool “Claude” in his honour.

) Information theory treats information itself as a measurable, statistical quantity like mass or energy.

The MSK researchers were able to measure the information using single-cell technology, which allows them to study individual cells and see which genes are active.

The technique analyses the relationship between the distributions of two different features of the same T cell:

  • One feature is the genetic sequence of the T cell receptor, which is like a unique genetic barcode that determines what the T cell can recognise.
     
  • Another feature is the cell’s gene expression pattern. It reveals what kind of state the cell is in and what it may be doing. For example: Is the T cell active, primed to recognise a cancer cell, exhausted (dysfunctional), or completely “naive” — meaning it hasn’t yet encountered its specific target antigen?

TCRi essentially measures the strength of the correlation between a T cell receptor’s “clonotype” (the barcode) and its gene expression pattern (the cell state or “phenotype”).

In other words, if you know a receptor’s identity, how well can you predict a T cell’s state?

“Our approach can help us understand T cells more completely by combining two kinds of information from a single cell within the mathematical framework of information theory,” Dr. Greenbaum says.

“Essentially, we are looking at how well the T cell’s receptor is communicating with its cell state. At a large scale, we can quantify data about T cell response — or non-response — to therapies that we are testing in clinical trials and immune monitoring efforts.”

The advance represented by TCRi is that it combines the two pieces of information in a balanced way within the framework of information theory.

Instead of saying a given T cell is “type X,” it can assign probabilities, such as saying a cell is 80% likely to be one state and 20% another.

This gives a more accurate overall picture for large amounts of data.

In analysing the data from more than 167,000 T cells from cancer patients who had received checkpoint inhibitors, the researchers wanted to see if there was a difference between responders and non-responders (patients in whom T cells were not activated).

One result was a bit unexpected.

They found that a lower correlation between receptor and cell state made the T cells more likely to respond to immunotherapy drugs.

  • In non-responders, the T cells’ clonotype and phenotype were more tightly correlated and less open to outside influence. This tight connection existed before treatment started, and the link often increased after therapy began.
     
  • In responders, the link between clonotype and phenotype was looser prior to treatment — the T cells were in a more “receptive” or flexible state that allowed more productive responses when the immunotherapy unlocked them. 

This finding sheds more light on T cell behaviour, including which types of T cells might be more likely to respond to immunotherapy drugs.

Dr. Greenbaum, who is also Co-Director of Neoantigen Discovery at the Olayan Centre for Cancer Vaccines at MSK, says TCRi has already been used at MSK to monitor a patient’s response to vaccines, including an investigational personalised pancreatic cancer vaccine being tested at MSK.

In a phase 1 trial, 50% of vaccinated patients responded to the vaccine.

Six out of eight who responded remained cancer free after six years of follow-up.

Understanding why some patients respond while others don’t is important to extending the potential benefit of a promising treatment.

“This tool offers a way to get a much clearer picture of what is biologically meaningful in T cell behaviour,” Dr. Greenbaum says.

“Not only is it helping us to better understand and predict the initial response to cancer vaccines, we also are monitoring how the T cell receptors — and the cell states — change over time as a result of the vaccine. Being able to monitor and assess this is going to be very important for any kind of immunotherapy that targets T cells and is a major priority at MSK.”

  • Immunotherapy activates T cells to recognise and destroy cancer cells, but the behaviour of T cells is hard to predict — as a result, immunotherapy often doesn’t work. 
  • MSK researchers have developed a new computational method, called TCRi (for TCR information), to better understand why some T cells don’t respond to immunotherapy. 
  • Using TCRi to analyse more than 167,000 T cells from cancer patients, they found a surprising pattern: T cells that were “flexible” — meaning the genetic makeup of their receptors was only loosely correlated to their behaviour — were more likely to respond to immunotherapy. 
  • TCRi is already being used at MSK to monitor responses to cancer vaccines and could help researchers understand why immunotherapies work for some patients but not for others.

Source: Memorial Sloan Kettering Cancer Center